Stay updated with breaking news from Beckley Psytech. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
In an exciting collaboration, modern mental health company, Clerkenwell Health, and Beckley Psytech, a clinical-stage biotechnology company, have launched a phase 2a study aimed at investigating a potential breakthrough treatment for alcohol use disorder (AUD).
NOVEL PSYCHEDELIC COMPOUND TO BE TESTED FOR TREATMENT OF ALCOHOL USE DISORDER Novel psychedelic compound, combined with psychological support, will be explored as a potential new treatment for people living with alcohol use disorder (AUD).The trial uses Beckley Psytech’s lead candidate BPL-003, a short-du...
27.03.2024 - - A single dose of BPL-003 demonstrated a rapid and durable antidepressant effect in TRD patients, with 45% of patients in clinical remission at week 12 - 55% of patients achieved a clinical response on the day after dosing and this rate of ... Seite 1
The short-acting psychedelic, BPL-003, resulted in rapid, durable depression symptom reduction in patients with TRD.